Contract Manufacturing Outsourcing (CMO) for Sterile Injectables Market is Projected to Grow at a CAGR of 9.10% by 2032: Visiongain Reports Ltd

Visiongain has published a new report.

Contract manufacturing outsourcing (CMO) of sterile injectables

2022-2032. Sterile Injectable Contract Manufacturing Outsourcing (CMO) Profile and Market Segment Forecast by Molecule Type (Small Molecule, Large Molecule), Type (Monoclonal Antibodies (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins ) includes market segments by , Blood Factors, Peptide Antibiotics, Others), Market Segment by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious Diseases, Others), Market Segment by Container Type (Bottles, Ampoules, Vials, Prefilled Syringes) , bags), market segments by route of administration (subcutaneous (SC), intravenous (IV), intramuscular (IM), and others), as well as COVID-19 impact analysis and recovery pattern analysis (“V” “W”, “U”, “L”), major companies, regions, and country profiles.

The CMO of sterile injectables market is valued at USD 19,090.4 million in 2021 and is projected to grow at a CAGR of 9.10% during the forecast period 2022-2032.

Increased investment in infrastructure and drug development to boost market development

The manufacturing processes and equipment required for sterile injectables require large investments. Due to the lack of capital, many pharmaceutical companies in the US and Europe are looking to other companies for investment. Jubilant Pharma, a wholly owned subsidiary of Jubilant Pharmova, announced in June 2021 that he would invest US$92 million to expand its sterile injectable production capacity at its Spokane facility. The investment will place 400 vials of injectable filler in Spokane, increasing the facility’s capacity by 50%. Additionally, Pfizer announced in December 2022 that it will invest $750 million to expand its sterile injection facility in the United States. Kalamazoo is one of Pfizer’s largest factories and manufactures more than 144 pharmaceutical products, including sterile injectables, liquids and semisolids. As a result of these factors, the sterile injectable market is projected to grow during the forecast period.

Download a limited sample of the report

How has the expansion of clinical trial opportunities in Asia Pacific positively impacted contract manufacturing outsourcing (CMO) in the sterile injectable drug market?

The clinical trials business is in high demand due to the growing number of modern medical technologies and increasing need for novel drugs. Additionally, the drug development process is fraught with peril for pharmaceutical and biotech companies, leading to significantly lower approval rates and associated high costs. This will restrain the growth of the clinical trials market. Results show that outsourcing clinical trials to contract research organizations (CROs) saves sponsors significant time and money, allowing them to focus on drug discovery and improving market prospects.

How can this report help me?

Visiongain’s 361 page report contains 131 tables and 180 charts/graphs. Our new study is suitable for those who require a commercial and in-depth analysis of the CMOs of the sterile injectables market along with an in-depth segmental analysis of the market. Our new research helps assess the overall global and regional market for sterile injectable contract manufacturing outsourcing (CMO). Obtain financial analysis of the overall market and various segments including molecule type, type, application, container type and route of administration to gain higher market share. His CMO in this rapidly growing sterile injectable market sees great opportunities. Find out how you can take advantage of existing and upcoming opportunities in this market to generate revenue in the near future. Additionally, the report can help improve strategic decision-making, frame growth strategies, enhance analysis of other market players, and maximize company productivity.

What are the current market drivers?

Growing demand for biologics is expected to drive demand, driving market growth

An increase in the number of complex medicines and the growing need to reduce R&D costs may lead to an increase in demand, which in turn contributes to market growth. Increased R&D outsourcing and his CDMO proficiency is expected to contribute to increased demand for contract manufacturing of sterile injectables for Life His science companies. Vendors in growth markets such as India and China offer his CDMO services at discounted rates, which has led to manufacturing outsourcing.

Prefilled Syringes Offering Favorable Growth Prospects

Prefilled syringes are often used to treat chronic conditions such as heart disease, diabetes, and autoimmune diseases where patients must self-administer their medication. As a result, the market for prefilled syringes is driven by the worldwide increase in the incidence and prevalence of chronic and lifestyle diseases. Demand for self-injectors has also increased as a result of their ease of use and safety. The demand for effective and user-friendly medication systems is one factor driving market expansion, along with increasing efforts by physicians to reduce hospital failures. Rapid development of feature-rich devices that underpin improvements in technology that make patient self-injection safer and more convenient will drive the market expansion throughout the forecast period.

Download a limited sample of the report

Where are the market opportunities?

Increased investment in technologically sophisticated sterile injectable drug manufacturing facilities is expected to drive market growth

Increasing investment in technologically advanced sterile injectable manufacturing facilities will boost global CMOs in the sterile injectable drug market. For example, in April 2022, Delpharm Company will invest his US$29.7 million in a sterile line to manufacture prefilled syringes. Delpharm will begin construction of a new building dedicated to manufacturing these dosage forms in April 2021, and production is expected to begin by the end of the first quarter of 2023. Delpharm Tours facilities will be equipped with state-of-the-art technology, including isolators. From 25 million a year he will be able to produce 30 million syringes.

competitive environment

Adare Pharma Solutions is the major player operating in the CMO of the sterile injectable drug market. Aenova Group; Almac Group; Avara Pharmaceutical Services, Inc.; Baxter International Inc.; Boehringer Ingelheim International GmbH; Grifols SA; Hikma Pharmaceuticals PLC; Jubilant Pharmova Ltd.; Lonza; Nexus Pharmaceuticals, Inc.; Patheon, Inc. (Thermo Fischer); Operating in his CMO of the sterile injectables market, these key players have adopted various strategies such as collaboration, geographic expansion, M&A, investment in R&D, and new product launches.

Recent development

• In January 2022, Pharmon Beijing Co., Limited acquired Aesica Pharmaceuticals Limited from Recipharm Group.

• In January 2022, Forbion, along with Lonza, announced an expanded collaboration to include small molecule development and manufacturing.

To access the data contained in this document, please contact us by email

oliver.davison@visiongain.com

For sectors, please click the following link.

Do you have a custom requirement that we can help with? Need a specific country, geographic region, market segment, or specific company information? Contact us today. We can discuss your needs and see how we can help.

oliver.davison@visiongain.com

About vision gain

Visiongain is one of the fastest growing and most innovative independent market intelligence providers.

market research report

Additions are made to our extensive portfolio each year. These reports provide in-depth analysis across 18 industries worldwide. Covering a 10-year forecast, the report is hundreds of pages long and contains detailed market analysis and valuable competitive intelligence data. Visiongain has many synergies in various vertical markets. These markets include the automotive, aerospace, chemical, cyber, defense, energy, food and beverage, materials, packaging, pharmaceutical, and utility sectors. Our customized and syndicated market research reports provide bespoke market intelligence tailored to your unique business needs.

contact:

Oliver Davison

Visiongain report only

Phone: +44 (0) 20 7336 6100

Email:

oliver.davison@visiongain.com

web:

www.visiongain.com